NCT06226727View on ClinicalTrials.gov

"A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1019 and Co-administration of BR1019-1 and BR1019-2"

PHASE1CompletedINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

February 14, 2024

Primary Completion Date

March 31, 2024

Study Completion Date

March 31, 2024

Conditions
Type 2 Diabetes MellitusEssential Hypertension
Interventions
DRUG

BR1019

One tablet administered alone

DRUG

BR1019-1

One tablet administered alone

DRUG

BR1019-2

One tablet administered alone

Trial Locations (1)

08779

Clinical Research Center, H PLUS Yangji Hospital, Seoul

Sponsors
All Listed Sponsors
lead

Boryung Pharmaceutical Co., Ltd

INDUSTRY